Overview
Indirect Coomb’s test is an immunohematological assay used to detect free antibodies present in a patient’s serum that are directed against red blood cell antigens. It identifies in-vitro sensitization of red blood cells by incomplete antibodies, which are not detectable on circulating cells. The test uses an anti-human globulin reagent to demonstrate antibody binding through visible agglutination. Indirect Coombs’ test plays a vital role in transfusion medicine and antenatal screening by identifying antibodies that may cause hemolytic reactions.
Symptoms
Indirect Coomb’s test is usually performed as a screening or diagnostic investigation rather than based on specific symptoms. However, patients may present with anemia, jaundice, fatigue, breathlessness, or a history of transfusion reactions. In pregnancy, there may be no maternal symptoms, but the fetus may be at risk of hemolytic disease. Previous unexplained transfusion reactions or poor transfusion response may prompt testing.
Causes
A positive Indirect Coomb’s test occurs due to the presence of circulating antibodies against red blood cell antigens. These antibodies may develop following blood transfusions, pregnancy with fetal–maternal blood group incompatibility, autoimmune hemolytic anemia, or exposure to foreign red cell antigens. The antibodies remain free in the serum and can sensitize reagent red cells during the test, leading to agglutination when anti-human globulin is added.
Risk Factors
Risk factors for a positive Indirect Coomb’s test include previous blood transfusions, multiple pregnancies, Rh incompatibility, autoimmune disorders, and prior sensitization to red cell antigens. Women with a history of stillbirths, recurrent miscarriages, or hemolytic disease of the newborn are at increased risk. Patients requiring repeated transfusions or those with chronic hematological disorders are also more susceptible.
Prevention
Prevention of complications related to positive Indirect Coomb’s test relies on early detection and monitoring. Routine antenatal screening helps prevent hemolytic disease of the fetus and newborn through timely administration of anti-D immunoglobulin. Proper blood grouping, antibody screening, and cross-matching before transfusion reduce the risk of hemolytic transfusion reactions. Adherence to standardized testing protocols ensures accurate results and safe clinical management.
